Lista de obras - Ernest Nadal - Dominio Público Uruguay

A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.

artículo científico publicado en 2014

A Novel Serum 4-microRNA Signature for Lung Cancer Detection.

scientific article published on 23 July 2015

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

scientific article published on 22 September 2020

A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer

artículo científico

Abstract LB-155: Identification of a DNA methylation signature in liquid biopsy for early non-small cell lung cancer (NSCLC) diagnosis

article published in 2016

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13

artículo científico publicado en 2023

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

artículo científico publicado en 2021

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

artículo científico publicado en 2016

Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation

artículo científico publicado en 2019

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer

artículo científico publicado en 2010

Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature

artículo científico publicado en 2015

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.

artículo científico publicado en 2017

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2017

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

artículo científico publicado en 2015

Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.

artículo científico publicado en 2013

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

artículo científico publicado en 2018

Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma

scientific article published on April 2014

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

artículo científico publicado en 2019

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer

artículo científico publicado en 2017

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

artículo científico publicado en 2020

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.

artículo científico publicado en 2018

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

scientific article published on 06 February 2019

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

artículo científico publicado en 2018

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

artículo científico publicado en 2018

Intrinsic cancer subtypes-next steps into personalized medicine

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

artículo científico publicado en 2018

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

artículo científico publicado en 2014

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

artículo científico publicado en 2015

Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

scientific article published on 13 June 2018

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

artículo científico publicado en 2020

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts

artículo científico publicado en 2014

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

scientific article published on 22 August 2019

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

scientific article published on 03 April 2019

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

artículo científico publicado en 2020

Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancer

scientific article published on 01 May 2011

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer

artículo científico publicado en 2011

Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancer

artículo científico publicado en 2018

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14)

artículo científico publicado en 2020

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2019

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

artículo científico publicado en 2017

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.

artículo científico publicado en 2015

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

artículo científico publicado en 2018

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

scientific article published on 03 May 2019

Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells

artículo científico publicado en 2020

Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

artículo científico publicado en 2018

The role of Dickkopf-3 overexpression in esophageal adenocarcinoma

artículo científico publicado en 2015

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes

scientific article published on 25 February 2019

Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes

artículo científico publicado en 2014

Lista de obras de Ernest Nadal

A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.

A Novel Serum 4-microRNA Signature for Lung Cancer Detection.

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer

Abstract LB-155: Identification of a DNA methylation signature in liquid biopsy for early non-small cell lung cancer (NSCLC) diagnosis

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation

Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer

Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Epigenetic regulation of vitamin D metabolism in human lung adenocarcinoma

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Intrinsic cancer subtypes-next steps into personalized medicine

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.

Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Paraneoplastic opsoclonus-myoclonus syndrome as a new and single manifestation of relapsing disease in a patient with small cell lung cancer

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer

Preoperative nutritional status assessment predicts postoperative outcomes in patients with surgically resected non-small cell lung cancer

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial

Starvation and antimetabolic therapy promote cytokine release and recruitment of immune cells

Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

The role of Dickkopf-3 overexpression in esophageal adenocarcinoma

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes

Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes